Saturday 17 October 2026
Export PASG’s income statement to Excel — free account
Passage Bio, Inc.
PASG Healthcare Biotechnology
In the quarter to June 2026, EPS grew 17.6% and free cash flow fell 59.8%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
3.48
0.12
−3.33%
Follow PASG
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(87.18%) | (113.78%) | (128.90%) | (169.09%) | |
| (48.69%) | (55.28%) | (61.53%) | (69.20%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(117.13%) | (158.14%) | (243.65%) | (810.41%) | |
Free Cash Flow per Share |
(10.17) | (9.56) | (9.37) | (10.43) | |
Free Cash Flow |
(32.32) | (30.34) | (30.04) | (33.48) | |
Capital Expenditures |
1.16 | 1.17 | 0.61 | 0.02 | |
| Other line items | |||||
Cash ROIC |
(38.52%) | (46.63%) | (66.63%) | (117.02%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.74 | 0.69 | 0.81 | 0.93 | |
Depreciation/Fixed assets |
0.20 | 0.21 | 0.79 | 0.00 | |
Capex/Depreciation |
1.12 | 1.37 | 0.92 | 0.04 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(10.53) | (9.93) | (9.56) | (10.44) | |
Capex per Share |
0.36 | 0.37 | 0.19 | 0.01 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates